<DOC>
	<DOCNO>NCT02402309</DOCNO>
	<brief_summary>This multi-center , randomize , double-blind , vehicle-controlled , parallel-group study design evaluate safety , PK , exploratory activity topically-applied NS2 dermatologic cream administer once-daily ( QD ) subject ichthyosis secondary Sjögren- Larsson Syndrome ( SLS ) . NS2 expect trap fatty aldehyde pathogenic SLS patient , thereby diminish lipid-aldehyde adduct formation likely result ichthyosis associated SLS , potentially reduce mild dermal inflammation characteristic SLS .</brief_summary>
	<brief_title>A Study Topical NS2 Cream Treat Ichthyosis Sjögren-Larsson Syndrome ( SLS )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Sjogren 's Syndrome</mesh_term>
	<mesh_term>Ichthyosis</mesh_term>
	<mesh_term>Sjogren-Larsson Syndrome</mesh_term>
	<criteria>Geneticallyconfirmed diagnosis SLS Active ichthyosis low extremity determine least moderate severity Evidence active infection Currently receive immunosuppressive therapy , include intermittent lowdose corticosteroid able willing suspend 2 week study Currently receive systemic topical retinoids , topically apply drug , supplement could interfere dermatologic examination finding Received investigational systemic topically administer drug within 30 day screen</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Sjögren-Larsson Syndrome</keyword>
	<keyword>SLS</keyword>
	<keyword>Ichthyosis</keyword>
	<keyword>FALDH Deficiency</keyword>
	<keyword>Neuro-ichthyosis</keyword>
	<keyword>Fatty Alcohol : NAD+ Oxidoreductase Deficiency</keyword>
	<keyword>Fatty Aldehyde Dehydrogenase Deficiency Disease</keyword>
	<keyword>Congenital Icthyosis Mental Retardation Spasticity Syndrome</keyword>
	<keyword>Spastic Neurologic Disorder</keyword>
	<keyword>Oligophrenia</keyword>
</DOC>